Talking to patients about St. John's wort

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 11, 2003, Pages 985-989

  Deshmukh, Rashmi ^a   Franco, Kathleen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BROMAZEPAM; CYCLOSPORIN; CYTOCHROME P450 3A4; DIAZEPAM; DIGOXIN; DOPAMINE; HERBACEOUS AGENT; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NON PRESCRIPTION DRUG; NORADRENALIN; ORAL CONTRACEPTIVE AGENT; PHOTOSENSITIZING AGENT; PLACEBO; PROTEINASE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFONAMIDE; TETRACYCLINE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; ENZYME INDUCTION; FATIGUE; HEADACHE; HUMAN; HYPERTENSIVE CRISIS; NAUSEA; PATIENT CARE; PHOTOTOXICITY; PHYSICIAN; RASH; RESTLESSNESS; REVIEW; SELF MEDICATION; SEROTONIN SYNDROME; SUPPLEMENTATION; SWEATING;

EID: 0345329531     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.11.985     Document Type: Review

References (29)

1. Hemlich N. Popularity of herbs; sprouts from publicity. USA Today. July 13, 1998.
2. Ernst E, Pittler MH. Herbal medicine. Med Clin North Am 2002; 86:149-161.
3. Laakman G, Schule C, Baghai T, Kieser M. St John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31(suppl 1):54-59.
4. Narstedt A, Butterweck V. Biologically active and other chemical constituents of the herb Hypericum perforatum. Pharmacopsychiatry 1997; 30:129-134.
5. Chaterjee SS, Nolder M, Koch E, Erdelmeier C. Antidepressant efficacy of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998; 31(suppl 1):7-15.
6. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake-inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31(suppl 1):16-21.
7. Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 1999; 816:358-363.
8. Franklin M, Chi J, Hockney R, et al. Neuroendocrine evidence of dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 1999; 46:581-584.
9. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30(suppl 1):108-112.
10. Teufel-Mayer R, Gleitz J. Effect of long-term administration of hypericin extracts on the affinity of the central serotonergic 5HT1A and 5HT2A receptors. Pharmacopsychiatry 1997; 30(suppl):113-116.
11. Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericin extract. J Geriatr Psychiatry Neurol 1994; 7(suppl 1):S60-S62.
12. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder. JAMA 2002; 287:1807-1814.
13. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978-1986.
14. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicenter study of treatment for eight weeks. BMJ 1999; 319:1534-1538.
15. Linde K, Mulrow CD. St. John's wort for depression. Cochrane Database Syst Rev. 2000; CD000448.
16. Gaster B, Holroyd J. St John's wort for depression: a systematic review. Arch Intern Med 2000; 160:152-156.
17. Shrader E, for the Study Group. Equivalence of St. John's wort extract (ZE 117) and fluoxetine. Int Clin Psychopharmacol 2000; 15:61-68.
18. Stevinson C, Ernst E. Hypericum for depression. An update of the clinical evidence. Eur Neuropsychopharmacol 1999; 9:501-505.
19. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159:1361-1366.
20. St. John's wort. In: Physicians Desk Reference for Herbal Medicines 2000. Medical Economics Company, 2000:719-725.
21. Markowitz JS, Donovan JL, DeVane L, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290:1500-1504.
22. McGuffin M, editor. Botanical Safety Handbook. Boca Raton, Fla: CRC Press, Inc., 1997:62-63.
23. Mathijssen R, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247-1249.
24. Mansky P, Straus S. St. John's wort: more complications for cancer patients (editorial). J Natl Cancer Inst 2002; 94:1187-1188.
25. Schneider RK, Levenson JL. Update in psychiatry. Ann Intern Med 2002; 137:671-677.
26. Brown RP, Gerbarg PL, Muskin PR. Complementary and alternative treatments in psychiatry. In: Tasman A, Kay J, Lieberman JA, editors. Psychiatry Therapeutics, Second Edition. Southern Gate, West Sussex, England: John Wiley and Sons, Ltd, 2003:449-485.
27. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001; 16:239-252.
28. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002; 136:42-53.
29. Adams KE, Cohen MH, Eisenberg D, Jonsen AR. Ethical considerations of complementary and alternative therapies in conventional medical settings. Ann Intern Med 2002; 137:660-664